PRNewsWire
02 Oct 2025, 12:10 UTC · 49w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
MoonLake's VELA-2 trial failed to achieve statistical significance in its week 16 primary endpoint due to higher-than-expected intercurrent events in the placebo arm. — The failure of a key clinical trial for the company's lead drug candidate fundamentally undermines its commercial viability and core valuation.
-1.00Shares of MoonLake fell by approximately 90% following the disclosure of the VELA-2 trial failure. — A 90% share price decline reflects a massive and immediate destruction of market capitalization and investor confidence in the company.
-0.90A law firm is investigating MoonLake for potential securities law violations, alleging the company made misleading statements regarding its trial designs and confidence in managing intercurrent events. — Securities fraud litigation introduces significant financial liability risks, management distraction, and potential reputational damage that pressures the stock further.
-0.60Continue reading
5 related stories
Search tags
Which stocks this story touches
The company is under investigation for securities fraud after a clinical trial failed to meet its primary endpoint and shares fell 90%.
The company is the subject of a securities fraud class action lawsuit.
The company is the subject of a securities fraud class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
13h ago
